DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Lodine (Etodolac) - Published Studies

 
 



Lodine Related Published Studies

Well-designed clinical trials related to Lodine (Etodolac)

A multicentric, randomized, comparative clinical trial to evaluate the efficacy and safety of S-etodolac in the treatment of osteoarthritis in Indian patients. [2010.07]

Efficacy and safety of etodolac-paracetamol fixed dose combination in patients with knee osteoarthritis flare-up: a randomized, double-blind comparative evaluation. [2010]

A multicentric, randomized, comparative clinical trial to evaluate the efficacy and safety of S-etodolac in the treatment of osteoarthritis in Indian patients. [2010]

Evaluation of adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs. [2007.03]

Etodolac versus dexamethasone effect in reduction of postoperative symptoms following surgical endodontic treatment: a double-blind study. [2006.06]

Well-designed clinical trials possibly related to Lodine (Etodolac)

The efficacy of prostaglandin E1 derivative in patients with lumbar spinal stenosis. [2009.01.15]

The efficacy of prostaglandin E1 derivative in patients with lumbar spinal stenosis. [2009.01.15]

COX-2 inhibition attenuates cough reflex sensitivity to inhaled capsaicin in patients with asthma. [2009]

WITHDRAWN: Non-aspirin, non-steroidal anti-inflammatory drugs for treating osteoarthritis of the knee. [2007.07.18]

Efficacy and safety of firocoxib in the management of canine osteoarthritis under field conditions. [2006.06]

[Postoperative pain management in clinics of otolaryngology] [2006]

Other research related to Lodine (Etodolac)

Comparative evaluation of efficacy and safety of etodolac and diclofenac sodium injection in patients with postoperative orthopedic pain. [2011.11]

Randomized double-blind trial of sulindac and etodolac to eradicate aberrant crypt foci and to prevent sporadic colorectal polyps. [2011.06.01]

The enantiomers of etodolac, a racemic anti-inflammatory agent, play different roles in efficacy and gastrointestinal safety. [2011]

Randomized double-blind trial of sulindac and etodolac to eradicate aberrant crypt foci and to prevent sporadic colorectal polyps. [2011]

Polymeric surfactant based etodolac chewable tablets: formulation and in vivo evaluation. [2010.12]

R-etodolac induces E-cadherin and suppresses colitis-related mouse colon tumorigenesis. [2010.12]

Efficacy and safety of etodolac-paracetamol fixed dose combination in patients with knee osteoarthritis flare-up: a randomized, double-blind comparative evaluation. [2010.09]

In-vivo gamma scintigraphic evaluation and determination of a gastro-resistant etodolac tablet in humans. [2010.07]

Preventive effects of etodolac, a selective cyclooxygenase-2 inhibitor, on cancer development in extensive metaplastic gastritis, a Helicobacter pylori-negative precancerous lesion. [2010.03.15]

Enhanced oral bioavailability of etodolac by self-emulsifying systems: in-vitro and in-vivo evaluation. [2010.02]

Preventive effects of etodolac, a selective cyclooxygenase-2 inhibitor, on cancer development in extensive metaplastic gastritis, a Helicobacter pylori-negative precancerous lesion. [2009.08.26]

Single dose oral etodolac for acute postoperative pain in adults. [2009.07.08]

Paradoxical effects of a selective cyclooxygenase-2 inhibitor, etodolac, on proliferative changes of forestomach in alloxan-induced diabetic rats. [2009.07]

Etodolac attenuates mechanical allodynia in a mouse model of neuropathic pain. [2009.04]

In vitro and in vivo characteristics of a thermogelling rectal delivery system of etodolac. [2009]

The risk of acute myocardial infarction with etodolac is not increased compared to naproxen: a historical cohort analysis of a generic COX-2 selective inhibitor. [2008.12]

The effects of etodolac, nimesulid and naproxen sodium on the frequency of sister chromatid exchange after enclused third molars surgery. [2008.10.31]

Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia. [2008.04]

Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. [2008.04]

Chemopreventive effects of a selective cyclooxygenase-2 inhibitor (etodolac) on chemically induced intraductal papillary carcinoma of the pancreas in hamsters. [2008.04]

Inhibitory effects of the cyclooxygenase-2 inhibitor, etodolac, on colitis-associated tumorigenesis in p53-deficient mice treated with dextran sulfate sodium. [2008.02]

Etodolac, a selective cyclooxygenase-2 inhibitor, induces upregulation of E-cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo. [2008.01]

Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia. [2007.12.20]

The effect of etodolac on experimental temporomandibular joint osteoarthritis in dogs. [2007.12]

In vitro and ex vivo permeation studies of etodolac from hydrophilic gels and effect of terpenes as enhancers. [2007.10]

R-etodolac (SDX-101) and the related indole-pyran analogues SDX-308 and SDX-309 potentiate the antileukemic activity of standard cytotoxic agents in primary chronic lymphocytic leukaemia cells. [2007.09]

Safety of selective cyclooxygenase-2 inhibitors and a basic non-steroidal anti-inflammatory drug (NSAID) in Japanese patients with NSAID-induced urticaria and/or angioedema: Comparison of meloxicam, etodolac and tiaramide. [2007.03]

Keratoconjunctivitis sicca associated with administration of etodolac in dogs: 211 cases (1992-2002). [2007.02.15]

Pharmacokinetics of etodolac in the horse following oral and intravenous administration. [2007.02]

Pulmonary-renal syndrome, diffuse pulmonary hemorrhage and glomerulonephritis, associated with Wegener's granulomatosis effectively treated with early plasma exchange therapy. [2007]

Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells. [2006.12]

Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults. [2006.11]

In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells. [2006.07]

Efficacy and safety of preoperative etodolac and butorphanol administration in dogs undergoing ovariohysterectomy. [2006.05]

Use of force plate analysis to assess the analgesic effects of etodolac in horses with navicular syndrome. [2006.04]

Expression of receptor for advanced glycation end products during rat tongue carcinogenesis by 4-nitroquinoline 1-oxide and effect of a selective cyclooxygenase-2 inhibitor, etodolac. [2006]

Antitumor effects of etodolac, a selective cyclooxygenase-II inhibitor, against human prostate cancer cell lines in vitro and in vivo. [2005.12]

Inhibitory effect of etodolac, a selective cyclooxygenase-2 inhibitor, on stomach carcinogenesis in Helicobacter pylori-infected Mongolian gerbils. [2005.08.26]

SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. [2005.07.15]

In vivo effects of carprofen, deracoxib, and etodolac on prostanoid production in blood, gastric mucosa, and synovial fluid in dogs with chronic osteoarthritis. [2005.05]

Separation of etodolac enantiomers by capillary electrophoresis. Validation and application of the chiral method to the analysis of commercial formulations. [2005.03]

Chemopreventative effect of a cyclooxygenase-2-specific inhibitor (etodolac) on chemically induced biliary carcinogenesis in hamsters. [2005.02]

Other possibly related research studies

The clinical pharmacology of cyclooxygenase-2-selective and dual inhibitors. [2006.09]

Poststreptococcal reactive arthritis. [2006.07]

Chemoprevention of spontaneous development of hepatocellular carcinomas in fatty liver Shionogi mice by a cyclooxygenase-2 inhibitor. [2006.08]

Effects of cyclooxygenase inhibition on the gastrointestinal tract. [2006.11]

High-grade slippage of the lumbar spine in a rat model of spondylolisthesis: effects of cyclooxygenase-2 inhibitor on its deformity. [2006.07.15]

Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk. [2006]

[Intestinal side effects of COX-2 inhibitors] [2006.03.27]

[Expression of cyclooxygenase (COX)-2 in astrocytic tumors and anti-tumor effects of selective COX-2 inhibitors] [2006.01]

Cyclooxygenase-2 inhibitor delays fracture healing in rats. [2005.08]

Anti-inflammatory, antinociceptive, and gastric effects of Hypericum perforatum in rats. [2005.08.08]

Preferential and non-selective cyclooxygenase inhibitors reduce inflammation during lipopolysaccharide-induced synovitis. [2005.04]

[Enhancement of nonsteroidal, anti-inflammatory drugs and preventive effect of antihistamines and disodium cromoglycate on wheat allergy] [2006.10]

NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. [2006.07]

Anti-inflammatory effects of tretinoin (all-trans-retinoic acid) 0.1% and adapalene 0.1% in rats. [2005.09]

The effects of non-steroidal anti-inflammatory drugs (selective and non-selective) on the treatment of periodontal diseases. [2005]

A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines. [2005.07]

Combined administration of ethodolac, ascorbic acid and radiotherapy as adjuvant therapies in an extrathoracic desmoid tumor with gross postoperative residual disease; case report and review of the literature. [2006.07]

Microscopic periradicular surgery: perioperative predictors for postoperative clinical outcomes and quality of life assessment. [2007.03]

Systematic review of clinical trials of treatments for osteoarthritis in dogs. [2007.02.15]

Effects of nonsteroidal anti-inflammatory drugs on postoperative renal function in adults with normal renal function. [2007.04.18]

Risk of serious upper gastrointestinal events with concurrent use of NSAIDs and SSRIs: a case-control study in the general population. [2007.04]

Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphoma. [2007.08]

Melanoma inhibition by cyclooxygenase inhibitors: role of interleukin-6 suppression, a putative mechanism of action, and clinical implications. [2007]

Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization. [2007.08]

Prescription of nonsteroidal anti-inflammatory drugs and co-prescribed drugs for mucosal protection: analysis of the present status based on questionnaires obtained from orthopedists in Japan. [2007]

Treatment of multiple myeloma with SDX-308. [2007.09]

Risk of upper gastrointestinal events with the use of various NSAIDs: a case-control study in a general population. [2007.08]

SDX-308 and SDX-101, non-steroidal anti-inflammatory drugs, as therapeutic candidates for treating hematologic malignancies including myeloma. [2007.10]

Edema in a patient receiving methadone for chronic low back pain. [2007.12.15]

Combination therapy of S-1 with selective cyclooxygenase-2 inhibitor for liver metastasis of colorectal carcinoma. [2008.03]

Regression of sporadic intra-abdominal desmoid tumour following administration of non-steroidal anti-inflammatory drug. [2008.02.08]

The role of non-steroidal anti-inflammatory drugs in the risk of development and treatment of hematologic malignancies. [2008.05.02]

Role of interleukin-1beta and tumor necrosis factor-alpha-dependent expression of cyclooxygenase-2 mRNA in thermal hyperalgesia induced by chronic inflammation in mice. [2008.03.18]

Comparative pharmacological study of free radical scavenger, nitric oxide synthase inhibitor, nitric oxide synthase activator and cyclooxygenase inhibitor against MPTP neurotoxicity in mice. [2008.09]

The role of non-steroidal anti-inflammatory drugs in the risk of development and treatment of hematologic malignancies. [2008.08]

The pattern of use of non-steroidal anti-inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people. [2008.08]

Radionuclide therapy for hepatocellular carcinoma: indication, cost and efficacy. [2008.04]

Gateways to clinical trials. [2008.06]

Variability in the response to cyclooxygenase inhibitors: toward the individualization of nonsteroidal anti-inflammatory drug therapy. [2009.08]

Reversible cerebral vasoconstriction syndrome: case report. [2009.08]

Systematic review of the management of canine osteoarthritis. [2009.04.04]

Cyclooxygenase (COX)-inhibiting drug reduces HSV-1 reactivation in the mouse eye model. [2009.03]

Role of COX-2 in cough reflex sensitivity to inhaled capsaicin in patients with sinobronchial syndrome. [2010.08.09]

Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a beta-adrenergic antagonist and a cyclooxygenase-2 inhibitor. [2010.03.01]

Selective and non-selective non-steroidal anti-inflammatory drugs and the risk of acute kidney injury. [2009.10]

Sacroiliitis and severe disability due to isotretinoin therapy. [2010.05]

Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). [2011.11.09]

Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. [2011.09]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017